

Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).

Title: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).

Publication year: 2021

Journal: Annals of internal medicine

Authors: American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.).

Society: European Respiratory Society

Origin country: International (Europe)

Target countries: Europe

DOI: 10.7326/M20-5831

PMID: 33017175

Source: <https://pubmed.ncbi.nlm.nih.gov/33017175/>

Ann Intern Med Ann Intern Med 3925 pheamercphys 0372351 aim Annals of Internal Medicine 0003-4819 1539-3704 pmc-is-collection-domain yes pmc-collection-title American College of Physicians - PMC COVID-19 Collection PMC7556654 PMC7556654.1 7556654 7556654 33017175 10.7326/M20-5831 aim-olf-M205831 1 Clinical Guidelines coronavirus Coronavirus Disease 2019 (COVID-19) hospital Hospital Medicine poc-eligible POC Eligible 3122457 COVID-19 2357 Health care providers 11279 SARS coronavirus 9715 Patients 6354 Upper respiratory tract infections 1541398 Pulmonary diseases 3282 Infectious diseases 8910 Epidemiology 7245 Lungs Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1) Use of Remdesivir to Treat COVID-19 Qaseem Amir MD, PhD, MHA <https://orcid.org/0000-0001-6866-7985> Yost Jennifer RN, PhD <https://orcid.org/0000-0002-3170-1956> Etzeandía-Ikobaltzeta Itziar PharmD, PhD <https://orcid.org/0000-0001-6606-649X> Abraham George M. MD, MPH <https://orcid.org/0000-0003-4296-8362> Jokela Janet A. MD, MPH <https://orcid.org/0000-0003-4324-4809> Forciea Mary Ann MD <https://orcid.org/0000-0002-1999-1145> Miller Matthew C. MD <https://orcid.org/0000-0001-7267-4897> Humphrey Linda L. MD, MPH * for the Scientific Medical Policy Committee of the American College of Physicians 1 American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.) 2 American College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.) 3 University of Massachusetts Medical School and Saint Vincent Hospital, Worcester, Massachusetts (G.M.A.) 4 University of Illinois College of Medicine at Urbana-Champaign, Champaign, Illinois (J.A.J.) 5 Penn Medicine, Philadelphia, Pennsylvania (M.A.F., M.C.M.) 6 Portland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (L.L.H.) Note: The Practice Points are developed by the SMPC of the ACP. The Practice Points are “guides” only and may not apply to all patients and all clinical situations. All Practice Points are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.

Financial Statement : Financial support for the development of the Practice Points comes exclusively from the ACP operating budget.

Disclosures: All financial and intellectual disclosures of interest were declared and potential conflicts were discussed and managed. Dr. Obley participated in discussion of the practice points but was recused from authorship and voting due to a moderate-level conflict of interest (author of supporting systematic review). A record of disclosures of interest and management of conflicts of interest is kept for each SMPC meeting and conference call and can be viewed at <https://www.acponline.org/>

about-acp/who-we-are/leadership/boards-committees-councils/scientific-medical-policy-committee/disclosure-of-interests-and-conflict-of-interest-management-summary-for-scientific-medical-policy . Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-5831 .

Corresponding Author: Amir Qaseem, MD, PhD, MHA, American College of Physicians, 190 N Independence Mall West, Philadelphia, PA 19106; e-mail, aqaseem@acponline.org .

Current Author Addresses: Dr. Qaseem: American College of Physicians, 190 N Independence Mall West, Philadelphia, PA 19106.

Dr. Yost: 800 Lancaster Avenue, Villanova, PA 19085.

Dr. Etxeandia-Ikobaltzeta: 1, Santa Margarita Hospital Street, Ground Floor 2, Office 1, Room 2, 20303 Irun, Gipuzkoa, Spain.

Dr. Abraham: 123 Summer Street, Suite 370, North Worcester, MA 01608.

Dr. Jokela: Carle Forum, 611 West Park, Urbana, IL 61801.

Dr. Forciea: 3615 Chestnut Street, Philadelphia, PA 19104.

Dr. Miller: Penn Medicine Radnor, 145 King of Prussia Road, Radnor, PA 19087.

Dr. Humphrey: 12310 Northwest Tualatin Avenue, Portland, OR 97229.

Author Contributions: Conception and design: A. Qaseem, J. Yost, I. Etxeandia-Ikobaltzeta, M.A. Forciea, R. Haeme, D.L. Kansagara, M. Marcucci, A. Obley.

Analysis and interpretation of the data: A. Qaseem, J. Yost, I. Etxeandia-Ikobaltzeta, J.A. Jokela, M.A. Forciea, L.L. Humphrey, R. Haeme, A.J. Obley.

Drafting of the article: A. Qaseem, J. Yost, I. Etxeandia-Ikobaltzeta, G.M. Abraham, R. Haeme, D.L. Kansagara.

Critical revision for important intellectual content: A. Qaseem, J. Yost, I. Etxeandia-Ikobaltzeta, G.M. Abraham, J.A. Jokela, M.A. Forciea, M.C. Miller, L.L. Humphrey, E.A. Akl, R. Andrews, R.M. Centor, R. Haeme, D.L. Kansagara, M. Marcucci, A.J. Obley.

Final approval of the article: A. Qaseem, J. Yost, I. Etxeandia-Ikobaltzeta, G.M. Abraham, J.A. Jokela, M.A. Forciea, M.C. Miller, L.L. Humphrey, E.A. Akl, R. Andrews, T.A. Bledsoe, R.M. Centor, R. Haeme, D.L. Kansagara, M. Marcucci.

Provision of study materials or patients: I. Etxeandia-Ikobaltzeta.

Statistical expertise: A. Qaseem, I. Etxeandia-Ikobaltzeta.

Administrative, technical, or logistic support: A. Qaseem, J. Yost.

Collection and assembly of data: J. Yost, I. Etxeandia-Ikobaltzeta.

5 10 2020 366899 M20-5831 14 10 2020 23 10 2020 01 08 2024 2020 American College of Physicians This article is made available via the PMC Open Access Subset for unrestricted re-use

for research, analyses, and text and data mining through PubMed Central. Acknowledgement of the original source shall include a notice similar to the following: "© 2020 American College of Physicians. Some rights reserved. This work permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited." These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2) 9 2 2021 M20-8101 Annals of Internal Medicine 10.7326/M20-8101 PMC7983309 33560862 Major Update: Remdesivir for Adults With COVID-19 9 2 2021 M20-8148 Annals of Internal Medicine 10.7326/M20-8148 PMC7901604 33560863 Remdesivir for Adults With COVID-19 5 10 2020 M20-5752 Annals of Internal Medicine 10.7326/M20-5752 PMC7564604 33017170 These rapid and living practice points from the American College of Physicians address the effectiveness and harms of remdesivir treatment in patients with COVID-19.